Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > AA and mBC

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Jun 19, 2023 1:35pm

150 Views

Post# 35503644

RE:RE:RE:RE:RE:RE:RE:RE:RE:AA and mBC

What puzzles me is the requirement for a two arm trial when there must have been many hundreds of trials that use paxlitaxol as one arm. Why not use those aggregated results as the control?

Why replicate something that has been done hundreds of times. I know that is not the "gold standard" for clinicial trials, but following the so called gold standard for drug approval has cost thousands of lives in the US waiting for trials on dying people. Look at the decacle for AIDS.

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?